UnknownPhase 1/2

Intravenous Labetalol Versus Hydralazine in Preeclampsia

Egypt40 participantsStarted 2024-04-01

Plain-language summary

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Who can participate

Age range25 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient with clinical diagnosis of sever preeclampsia Exclusion Criteria: Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion \-

What they're measuring

Cerebral blood flow

Timeframe: Pre intervention-after one hour of intervention

Trial details

NCT IDNCT06360601

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-20

Contact for this trial

shimaa zahraa

201550273707 Meikamal89@outlook.com

View on ClinicalTrials.gov More Preeclampsia Severe trials